BeiGene’s Post

View organization page for BeiGene, graphic

159,780 followers

Our investigational BCL2 inhibitor was recently granted Fast Track Designation by the FDA for relapsed/refractory Waldenström macroglobulinemia (#WM), recognizing the potential for this next-generation compound to address significant unmet need. Read more about WM and how we are leading with science to advance innovative #oncology medicines for patients: https://bit.ly/3x2LVeW

  • No alternative text description for this image
Mark Faridani

Machine Learning Engineering Manager

3w

Professor Mobasher has been one of the most inspirational figures in the field. Glad he is on the forefront of drug discovery.

Like
Reply
Meghal Vakil, M.S, RAC, CCRP

Associate Director, Regulatory affairs, Beigene

4w
Maycon Oliveira Amaral

Oncology Account Leader / Specialist GU Bayer Pharmaceuticals

4w

Parabéns

Like
Reply
Brenda Rogers, BBA

Dynamic Corporate Administrator & Event Planner | Project Manager | Chaos Coordinator | Facilitator

4w

Fantastic!! 👏

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics